{"id":"semaglutide-wegovy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating the GLP-1 receptor, semaglutide increases insulin secretion, decreases glucagon levels, and slows gastric emptying, leading to improved glycemic control and weight loss.","oneSentence":"Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:00.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in adults with obesity or overweight with at least one weight-related condition"},{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07272837","phase":"","title":"Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-04-01","conditions":"Type 2 Diabetes, Obesity, Semaglutide","enrollment":50},{"nctId":"NCT07465965","phase":"PHASE1","title":"A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults","status":"RECRUITING","sponsor":"Shanghai World Leader Pharmaceutical Co., Ltd.","startDate":"2026-03-02","conditions":"Overweight, Obesity","enrollment":60},{"nctId":"NCT07055607","phase":"","title":"A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2025-11-21","conditions":"Obesity","enrollment":1250},{"nctId":"NCT07423481","phase":"","title":"Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-06-01","conditions":"Obesity & Overweight","enrollment":3000},{"nctId":"NCT06852391","phase":"PHASE4","title":"JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-18","conditions":"Obesity (Disorder)","enrollment":74},{"nctId":"NCT05503927","phase":"","title":"A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-01-02","conditions":"Pregnancy, Obesity, Overweight","enrollment":1139},{"nctId":"NCT05872022","phase":"","title":"A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-07-05","conditions":"Pregnancy, Obesity, Overweight","enrollment":728},{"nctId":"NCT06468748","phase":"PHASE4","title":"The Effects of Semaglutide on Body Composition and Performance in Military Personnel","status":"WITHDRAWN","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2024-08-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT06299098","phase":"PHASE2","title":"A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-03-13","conditions":"Obesity","enrollment":1005},{"nctId":"NCT07275697","phase":"PHASE4","title":"Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study","status":"NOT_YET_RECRUITING","sponsor":"Emma Svennberg","startDate":"2025-12-15","conditions":"Atrial Fibrillation (AF), Obesity & Overweight","enrollment":200},{"nctId":"NCT07150975","phase":"PHASE3","title":"Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-09-23","conditions":"Obesity/Overweight in Adult","enrollment":420},{"nctId":"NCT06283667","phase":"","title":"Special Use - Results Surveillance on Long-term Use With Wegovy®","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2024-06-11","conditions":"Obesity","enrollment":1000},{"nctId":"NCT06745284","phase":"PHASE1","title":"A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-03-26","conditions":"Obesity","enrollment":60},{"nctId":"NCT05897398","phase":"","title":"SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2024-06-10","conditions":"Obesity, Bariatric Surgery, Binge Eating Disorder","enrollment":1100},{"nctId":"NCT07090343","phase":"PHASE3","title":"Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement","status":"NOT_YET_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2026-04-01","conditions":"Aortic Stenosis, Heart Failure","enrollment":826},{"nctId":"NCT06908694","phase":"PHASE4","title":"Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-07-02","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT06967389","phase":"","title":"Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity","status":"RECRUITING","sponsor":"John Bauer","startDate":"2025-06-12","conditions":"Obesity and Overweight, Obese Adolescents, Weight Management","enrollment":50},{"nctId":"NCT07036172","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-01-03","conditions":"Obesity Control","enrollment":460},{"nctId":"NCT07018544","phase":"","title":"A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2024-11-19","conditions":"Obesity and Overweight","enrollment":840},{"nctId":"NCT06715514","phase":"NA","title":"Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes","status":"RECRUITING","sponsor":"Lia Bally","startDate":"2025-02-18","conditions":"Menopause, Type 2 Diabetes","enrollment":96},{"nctId":"NCT06830343","phase":"PHASE1","title":"The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity","status":"RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2025-02-27","conditions":"Overweight or Obesity","enrollment":66},{"nctId":"NCT06764056","phase":"NA","title":"Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","status":"NOT_YET_RECRUITING","sponsor":"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","startDate":"2025-01","conditions":"Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT06738979","phase":"PHASE3","title":"A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-03","conditions":"Obesity","enrollment":408},{"nctId":"NCT06633783","phase":"PHASE3","title":"A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","startDate":"2024-10-30","conditions":"Obesity","enrollment":370},{"nctId":"NCT06426446","phase":"NA","title":"Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-01","conditions":"Obesity","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Semaglutide(Wegovy® )","genericName":"Semaglutide(Wegovy® )","companyName":"Gan & Lee Pharmaceuticals.","companyId":"gan-lee-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. Used for Chronic weight management in adults with obesity or overweight with at least one weight-related condition, Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}